MosheTalpazMD

PubMed

• 3 citations
  Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
  Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan-Carlos Hernandez-Boluda, Prithviraj Bose
  Blood. 2024-10-24
• Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
  Claire N Harrison, Ruben Mesa, Moshe Talpaz, Vikas Gupta, Aaron T Gerds
  Clinical Lymphoma, Myeloma & Leukemia. 2024-10-16
• Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, co...
  Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy
  The Lancet. Haematology. 2024-10-01

Journal Articles

• Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors  
  Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
• Leukemia Inhibitory Factor Functions in Parallel with Interleukin-6 to Promote Ovarian Cancer Growth  
  Karen McLean, Ronald J Buckanovich, Moshe Talpaz, Nature
• The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid Leukemia  
  Dale L Bixby, Ivan P Maillard, Moshe Talpaz, Leukemia Research

Abstracts/Posters

• Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized...
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
  Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018